Product Description
Sodium thiosulphate (STS), an antioxidant and calcium chelating agent, has been used for the treatment of calciphylaxis. However, its efficacy and safety have not been systematically analysed and evaluated. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/28603903/)
Mechanisms of Action: Cyanide Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Australia | Bangladesh | Belgium | Chile | China | Colombia | Dominican Republic | European Medicines Agency | France | Germany | Greece | Hong Kong | Iceland | India | Lithuania | Malaysia | New Zealand | Russia | Slovakia | Spain | Sweden | Taiwan | Thailand | United Kingdom | United States | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Allerderm
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, France, Germany, Italy, Netherlands, Spain, United States
Active Clinical Trial Count: 6
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Dermatitis, Allergic Contact|Dermatitis, Atopic|Dermatitis, Contact
Phase 2: Breast Cancer|Dermatomyositis|Head and Neck Cancer|Hypopharyngeal Cancer|Laryngeal Cancer|Mouth Cancer|Oropharyngeal Cancer|Papilloma|Scleroderma, General|Squamous Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 2023-507972-35-00 | P3 |
Withdrawn |
Dermatitis, Contact|Dermatitis, Atopic|Dermatitis, Allergic Contact |
2026-01-01 |
2025-05-02 |
Treatments |
|
| Safety and Efficacy Trial | P3 |
Completed |
Dermatitis, Allergic Contact|Dermatitis, Contact |
2025-01-30 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
| NCI-2020-05752 | P2 |
Completed |
Laryngeal Cancer|Oropharyngeal Cancer|Papilloma|Mouth Cancer|Hypopharyngeal Cancer|Squamous Cell Carcinoma|Head and Neck Cancer |
2023-05-31 |
2024-06-28 |
Primary Endpoints|Study Completion Date|Treatments |
|
| BYON5667.002 | P2 |
Completed |
Breast Cancer |
2023-04-19 |
39% |
2023-12-16 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| ITS Pilot | P2 |
Active, not recruiting |
Scleroderma, General|Dermatomyositis |
2021-10-16 |
2022-03-13 |
Treatments |
|
| 2023-507972-35-01 | P3 |
Not yet recruiting |
Dermatitis, Contact|Dermatitis, Allergic Contact |
2026-01-01 |
2025-05-02 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/08/2025 |
News Article |
Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 |
|
05/07/2025 |
News Article |
Children's Hospital Los Angeles Leads Development of First Machine Learning Tool to Predict Risk of Cisplatin-Induced Hearing Loss |
|
04/21/2025 |
News Article |
Dechlorination Chemical Market Size to Lead USD 20.58 Bn by 2034, says Towards chem and Materials Consultants |
|
04/15/2025 |
News Article |
Norgine strengthens rare disease portfolio with acquisition of Theravia |